The Economic and societal burden of multiple sclerosis on lebanese society: a cost-of-illness and quality of life study protocol

References

• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–286.
   PubMed Web of Science ®Google Scholar
• Compston A, Winedl H, Kieseier B. Coles. Multiple sclerosis Lancet. 2008;372:1502–1517.
   Google Scholar
• Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun. 2014;48:134–142.
   PubMed Web of Science ®Google Scholar
• Noteworthy J, Lucchinetti C, Rodriguez M, et al. Medical progress: multiple sclerosis. New Engl J Med. 2000;343:938–952.
   PubMed Web of Science ®Google Scholar
• Zindler E, Zipp F. Neuronal injury in chronic CNS inflammation. Best Pract Res Clin Anaesth. 2010;24(4):551–562.
   PubMedGoogle Scholar
• De Judicibus MA, McCabe MP. The impact of the financial costs of multiple sclerosis on quality of life. Int J Behav Med. 2007;14(1):3–11.
   PubMed Web of Science ®Google Scholar
• Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS. Mult Scler J. 2020;26(14):1816–1821.
   PubMed Web of Science ®Google Scholar
• Rice DP. Estimating the cost of illness. Am J Public Health Nations Health. 1967;57(3):424–440.
   PubMed Web of Science ®Google Scholar
• Larg A, Moss JR. Cost-of-illness studies. Pharmacoeconomics. 2011;29(8):653–671.
   PubMed Web of Science ®Google Scholar
• Németh G. Health related quality of life outcome instruments. Eur Spine J. 2006;15(S1):S44–S51.
   PubMedGoogle Scholar
• Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler J. 2017;23(8):1123–1136.
   PubMed Web of Science ®Google Scholar
• Campbell JD, Ghushchyan V, McQueen RB, et al. Burden of multiple sclerosis on direct, indirect costs and quality of life: national US estimates. Mult Scler Relat Disord. 2014;3(2):227–236.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Teich V, Cavalcanti M, et al. Burden and cost of multiple sclerosis in Brazil. PLoS One. 2019;14(1):e0208837.
   PubMed Web of Science ®Google Scholar
• Purmonen T, Hakkarainen T, Tervomaa M, et al. Impact of multiple sclerosis phenotypes on burden of disease in Finland. J Med Econ. 2020;23(2):156–165.
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, van Munster ETL, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis study: the costs and utilities of MS patients in The Netherlands. J Med Econ. 2013;16(7):939–950.
   PubMedGoogle Scholar
• Karabudak R, Karampampa K, Çalışkan Z, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Turkey. J Med Econ. 2015;18(1):69–75.
   PubMed Web of Science ®Google Scholar
• Dahham J, Rizk R, and Kremer I, et al. Economic burden of multiple sclerosis in low-and middle‐income countries: a systematic review. PharmacoEconomics. 2021 39;789–807.
   PubMed Web of Science ®Google Scholar
• Yamout B, Barada W, Tohme R, et al. Clinical characteristics of multiple sclerosis in Lebanon. J Neurol Sci. 2008;270(1–2):88–93.
   PubMed Web of Science ®Google Scholar
• Yamout B, Issa Z, Herlopian A, et al. Predictors of quality of life among multiple sclerosis patients: a comprehensive analysis. Eur J Neurol. 2013;20(5):756–764.
   PubMed Web of Science ®Google Scholar
• Farran N, Ammar D, Darwish H. Quality of life and coping strategies in lebanese multiple sclerosis patients: a pilot study. Mult Scler Relat Disord. 2016;6:21–27.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173.
   PubMed Web of Science ®Google Scholar
• Ysrraelit C, Caceres F, Villa A, et al. ENCOMS: argentinian survey in cost of illness and unmet needs in multiple sclerosis. Arq Neuropsiquiatr. 2014;72:337–343.
   PubMed Web of Science ®Google Scholar
• Boyko A, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Russia. Mult Scler J. 2017;23(2_suppl):155–165.
   PubMed Web of Science ®Google Scholar
• Da Silva NL, Takemoto ML, Damasceno A, et al. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study. BMC Health Serv Res. 2016;16(1):1–12.
   PubMedGoogle Scholar
• Kobelt G, Lindgren P, Parkin D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional observational study in the UK. SSE/EFI Working Paper Series in Economics and Finance; 2000.
   Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg. 2006;77(8):918–926.
   PubMed Web of Science ®Google Scholar
• Kobelt G. Health economic issues in MS. International MS journal. 2006;13(1):17–26, 16.
   PubMedGoogle Scholar
• who.int [Internet]. Geneva; [2021]. 23 Feb 2021 : https://www.who.int/substance_abuse/research_tools/translation/e
   Google Scholar
• Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci. 2007;256:S5–S13.
   PubMed Web of Science ®Google Scholar
• Klineova S, Lublin FD. Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8(9):a028928.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale. EDSS Neurology. 1983;33(11):14441444.):14441444.
   PubMed Web of Science ®Google Scholar
• Hohol M, Orav E, Weiner H. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology. 1995;45(2):251–255.
   PubMed Web of Science ®Google Scholar
• Riewpaiboon A. Measurement of costs. J Med Assoc Thai. 2008;91:S28–37.
   PubMedGoogle Scholar
• Svendsen B, Myhr K-M, Nyland H, et al. The cost of multiple sclerosis in Norway. Eur J Health Econ. 2012;13(1):81–91.
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study results from five European countries. Mult Scler J. 2012;18(2_suppl):7–15.
   PubMedGoogle Scholar
• Palmer AJ, Colman S, O’Leary B, et al. The economic impact of multiple sclerosis in Australia in 2010. Mult Scler J. 2013;19(12):1640–1646.
   PubMed Web of Science ®Google Scholar
• Ernstsson O, Gyllensten H, Alexanderson K, et al. Cost of illness of multiple sclerosis-a systematic review. PloS One. 2016;11(7):e0159129.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Eriksson J, Phillips G, et al. The burden of multiple sclerosis 2015: methods of data collection, assessment and analysis of costs, quality of life and symptoms. Mult Scler J. 2017;23(2_suppl):4–16.
   PubMed Web of Science ®Google Scholar
• Chiwaula LS, Chirwa GC, Caltado F, et al. The value of informal care in the context of option B+ in Malawi: a contingent valuation approach. BMC Health Serv Res. 2016;16(1):1–7.
   PubMedGoogle Scholar
• Koopmanschap MA, van Exel NJA, van Den Berg B, et al. An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics. 2008;26(4):269–280.
   PubMed Web of Science ®Google Scholar
• Hodgson TA. Costs of illness in cost-effectiveness analysis. Pharmacoeconomics. 1994;6(6):536–552.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, and Claxton K, et al. Methods for the economic evaluation of health care programmes. Oxford city: Oxford university press; 2015.
   Google Scholar
• labor.gov.lb [Internet]. Lebanon [ cited 2021 Mar 12]. Available from: 574b61dd-1233-4507-9da1-d4a3e3a6129a.pdf (labor.gov.lb)
   Google Scholar
• wb.int [Internet]. Washington (DC): Lebanon [ cited 2021 Jul 15]. Available from: PPP conversion factor, GDP (LCU per international $) - Lebanon | Data (worldbank.org)
   Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–1736.
   PubMed Web of Science ®Google Scholar
• Janssen M, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–1727.
   PubMed Web of Science ®Google Scholar
• Rabin R, Charro F. EQ-SD: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–343.
   PubMed Web of Science ®Google Scholar
• Jongen PJ. Health-related quality of life in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs. 2017;31(7):585–602.
   PubMed Web of Science ®Google Scholar
• Bekairy AM, Bustami RT, Almotairi M, et al. Validity and reliability of the Arabic version of the the EuroQOL (EQ-5D). A study from Saudi Arabia. Int J Health Sci (Qassim). 2018;12(2):16.
   PubMedGoogle Scholar
• Aburuz S, Bulatova N, Twalbeh M, et al. The validity and reliability of the Arabic version of the EQ-5D: a study from Jordan. Ann Saudi Med. 2009;29(4):304–308.
   PubMed Web of Science ®Google Scholar
• Dolan P, Gudex C, Kind P, et al. The time trade‐off method: results from a general population study. Health Econ. 1996;5(2):141–154.
   PubMed Web of Science ®Google Scholar
• Fernández O, Fernández V, Baumstarck-Barrau K, et al. Validation of the spanish version of the multiple sclerosis international quality of life (musiqol) questionnaire. BMC Neurol. 2011;11(1):1–10.
   PubMedGoogle Scholar
• Simeoni M, Auquier P, Fernandez O, et al. Validation of the multiple sclerosis international quality of life questionnaire. Mult Scler J. 2008;14(2):219–230.
   PubMed Web of Science ®Google Scholar
• Farran N, Safieddine BR, Bayram M, et al. Factors affecting MS patients’ health-related quality of life and measurement challenges in Lebanon and the MENA region. Multiple Sclerosis Journal–Experimental, Translational and Clinical. 2020;6(1): 2055217319848467.
   Google Scholar
• Risco J, Maldonado H, Luna L, et al. Latitudinal prevalence gradient of multiple sclerosis in Latin America. Mult Scler J. 2011;17(9):1055–1059.
   PubMed Web of Science ®Google Scholar
• Romero M, Arango C, Alvis N, et al. Costos de la esclerosis múltiple en Colombia. Value Health. 2011;14(5):S48–S50.
   PubMed Web of Science ®Google Scholar
• Daccache C, Rizk R, and Dahham J, et al. Economic evaluation guidelines in low- and middle-income countries: a systematic review. Int. J. Technol. Assess. Health Care. Forthcoming 2021
   PubMed Web of Science ®Google Scholar
• Gold M. Cost-effectiveness in health and medicine Oxford. New York: Oxford University Press; 1996.
   Google Scholar
• Lavelle TA, D’Cruz BN, Mohit B, et al. Family spillover effects in pediatric cost-utility analyses. Appl Health Econ Health Policy. 2019;17(2):163–174.
   PubMed Web of Science ®Google Scholar
• Fernandes N Economic effects of coronavirus outbreak (COVID-19) on the world economy. Available at SSRN 3557504. 2020.
   Google Scholar
• Schnitzler L, Janssen LM, and Evers SM, et al. The broader societal impacts of COVID-19 and the growing importance of capturing these in health economic analyses. Int J Technol Assess Health Care. 2021;37.
   PubMed Web of Science ®Google Scholar
• Tarricone R. Cost-of-illness analysis: what room in health economics? Health Policy. 2006;77(1):51–63.
   PubMed Web of Science ®Google Scholar
• Cortaredona S, Ventelou B. The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases. BMC Med. 2017;15(1):1–11.
   PubMedGoogle Scholar
• Severens JL, Mulder J, Laheij RJ, et al. Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in The Netherlands. Soc Sci Med. 2000;51(2):243–249.
   PubMed Web of Science ®Google Scholar
• Solans M, Pane S, Estrada MD, et al. Health‐related quality of life measurement in children and adolescents: a systematic review of generic and disease‐specific instruments. Value Health. 2008;11(4):742–764.
   PubMed Web of Science ®Google Scholar
• Mielck A, Vogelmann M, Leidl R. Health-related quality of life and socioeconomic status: inequalities among adults with a chronic disease. Health Qual Life Outcomes. 2014;12(1):1–10.
   PubMedGoogle Scholar
• Panzini RG, Mosqueiro BP, Zimpel RR, et al. Quality-of-life and spirituality. Int Rev Psychiatry. 2017;29(3):263–282.
   PubMed Web of Science ®Google Scholar
• Luz A, Santatiwongchai B, Pattanaphesaj J, et al. Identifying priority technical and context-specific issues in improving the conduct, reporting and use of health economic evaluation in low-and middle-income countries. Health Res Policy Syst. 2018;16(1):1–12.
   PubMedGoogle Scholar
• Clabaugh G, Ward MM. Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost. Value Health. 2008;11(1):13–21.
   PubMed Web of Science ®Google Scholar
• Onukwugha E, McRae J, Kravetz A, et al. Cost-of-illness studies: an updated review of current methods. Pharmacoeconomics. 2016;34(1):43–58.
   PubMed Web of Science ®Google Scholar
• Franken M, Le Polain M, Cleemput I, et al. Similarities and differences between five European drug reimbursement systems. Int J Technol Assess Health Care. 2012;28(4):349–357.
   PubMed Web of Science ®Google Scholar
• Welte R, Feenstra T, Jager H, et al. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics. 2004;22(13):857–876.
   PubMed Web of Science ®Google Scholar
• Wehbi M. COVID19: Impact on lebanese economy. Int J Res Sci. 2020;9(4):1648–1652.
   Google Scholar
• Devi S. Lebanon faces humanitarian emergency after blast. Lancet. 2020;396(10249):456.
   PubMed Web of Science ®Google Scholar
• Leão T, Campos-Matos I, Bambra C, et al. Welfare states, the great recession and health: Trends in educational inequalities in self-reported health in 26 European countries. PloS One. 2018;13(2):e0193165.
   PubMed Web of Science ®Google Scholar